ESMO World Congress on Gastrointestinal Cancer 2016

Oncology Meeting Resources

29 Jun - 02 Jul 2016, Barcelona, Spain

World GI 2016 Square Image

The ESMO World Congress on Gastrointestinal Cancer is the premier global event in the field, encompassing malignancies affecting every component of the gastrointestinal tract and aspects related to the care of patients with gastrointestinal cancer, including screening, diagnosis and the latest management options for common and uncommon tumours.

Abstracts, presentations and webcasts from the ESMO World GI 2016 Congress are now available here to ESMO members. The use of these presentations is for personal educational purposes only. ESMO thanks the authors for their generosity.





Format available

https://oncologypro.esmo.org/Meeting-Resour...-in-Albania-a-hepatitis-B-virus-endemic-area

Albania remains a high hepatitis B virus endemic country, despite the evident reduction of HBsAg in the general non-vaccinated population from 18% to 9.5% after the implementation of the hepatitis B vaccination program (1).

Date: 29 Jun 2016
Presenter: F. Kraja
Resources: Abstract

https://oncologypro.esmo.org/Meeting-Resour...presenting-with-Hepatocellular-Carcinoma-HCC

The worldwide incidence of hepatocellular carcinoma (HCC) is increasing. The vast majority of cases occur in patients with underlying cirrhosis, and most patients present with disease that is too...

Date: 29 Jun 2016
Presenter: P. Spiliopoulou
Resources: Abstract

https://oncologypro.esmo.org/Meeting-Resour...c-marker-in-pancreatic-ductal-adenocarcinoma

Pancreatic ductal adenocarcinoma (PADC) is one of the principal causes of cancer-related death worldwide. New therapeutic options against PADC had limited success.

Date: 29 Jun 2016
Presenter: M. Cruz Ramos
Resources: Abstract

https://oncologypro.esmo.org/Meeting-Resour...euroendocrine-tumours-PNET-in-Czech-Republic

In European population PNETs account for 1-5% of pancreatic tumours by incidence. There is a slight predominance of males. The prognosis is much better compared to common cancer of exocrine pancreas...

Date: 29 Jun 2016
Presenter: J. Barkmanova
Resources: Abstract

https://oncologypro.esmo.org/Meeting-Resour...icance-of-bcl-2-in-rectal-cancer-recurrences

The prognosis of colorectal carcinoma is still being evaluated by histological features. Recently, several studies on molecular biology have been carried out aiming the identification of new prognostic...

Date: 29 Jun 2016
Presenter: G. Botiralieva
Resources: Abstract

https://oncologypro.esmo.org/Meeting-Resour...V-pancreatic-cancer-a-population-based-study

Despite stage IV pancreatic cancer is considered one of the main causes of cancer mortality, there is a few number of population-based studies discussing the patterns of survival of this cancer.

Date: 29 Jun 2016
Presenter: M. Mousa
Resources: Abstract

https://oncologypro.esmo.org/Meeting-Resour...-metastatic-colorectal-cancer-mCRC-in-Russia

There is a large number of published Phase3 trials exploring the efficiency of chemotherapy combination with Mabs in mCRC patients. Some of them appear not demonstrating a significant gain in overall survival.

Date: 29 Jun 2016
Presenter: M. Fedyanin
Resources: Abstract

https://oncologypro.esmo.org/Meeting-Resour...y-for-gastric-cancer-a-report-of-92-patients

The aim of this study was to investigate the safety and feasibility of laparoscopic uncut Roux-en-Y anastomosis in the distant gastrectomy for gastric cancer.

Date: 29 Jun 2016
Presenter: Z. Xu
Resources: Abstract

https://oncologypro.esmo.org/Meeting-Resour...igh-risk-stage-II-colorectal-cancer-JSWOG-C2

Although 6 months oxaliplatin (OX)-based chemotherapy (modified FOLFOX6 or CAPOX) is one of the standard adjuvant chemotherapy for completely resected stage III colorectal cancer (CRC) in Japan, some...

Date: 29 Jun 2016
Presenter: H. Tanioka
Resources: Abstract

https://oncologypro.esmo.org/Meeting-Resour...-achieved-NED-after-liver-resection-for-mCRC

The concept of maintenance therapy in metastatic colorectal cancer (mCRC) after induction/adjuvant therapy is well established based on improvement in progression free survival (PFS) and the trend toward improvement in overall survival (OS).

Date: 29 Jun 2016
Presenter: M. Al-Hajeili
Resources: Abstract